DMPA-SC Evidence to Practice reports, resources, and references
The DMPA-SC Evidence to Practice workshops in 2018 and 2019 have gathered together family planning experts, including ministry officials, partners, and donors from more than 20 countries.
Meeting participants met to develop country strategies for increasing voluntary access to subcutaneous DMPA (DMPA-SC)* within a wide range of contraceptive methods and to inform related policy decisions with current evidence. The reports and resources below summarize the plenaries, presentations, and discussions held to inform country planning. For more information, visit the DMPA-SC Access Collaborative page; sign up for our newsletter; or email FPoptions@path.org.
- Second DMPA-SC Evidence to Practice Meeting | Dakar, Senegal | Meeting report (2019)
- DMPA-SC Evidence to Practice Meeting | Nairobi, Kenya | Meeting report (2018)
- Deuxième rencontre DMPA-SC : Des données à la mise en pratique | Dakar, Sénégal | Rapport de rencontre (2019)
- DMPA-SC : Des données à la mise en pratique | Nairobi, Kenya | Rapport de rencontre (2018)
Evidence and resource overviews
- Evidence at-a-glance: What we know about subcutaneous DMPA, a novel injectable contraceptive (from the Advocacy Pack for Subcutaneous DMPA)
- Resources: A list of references about subcutaneous DMPA (from the Advocacy Pack for Subcutaneous DMPA)
Effective delivery of DMPA-SC
- The Coming-of-Age of Subcutaneous Injectable Contraception (2018)
- Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries (2018)
- Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal (2014)
- Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects (2018)
Self-injection: Acceptability, feasibility, and effectiveness
- DMPA self-administration can improve contraceptive access, continuation, and autonomy (2018)
- A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection (2017)
- Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study (2017)
- Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial (2018)
- Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi (2018)
- Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda
- Costs of administering injectable contraceptives through health workers and self-injection: Evidence from Burkina Faso, Uganda, and Senegal (2018)
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.